News Stories Related To: Firms pitch new drugs for diabetes
Source: The Courier-Journal
Major pharmaceutical companies are fighting harder over the millions of patients with diabetes, a lucrative market because the pool of customers is growing with the obesity epidemic...
-
- Share:
-
-
-
-
-
- Read full report
Reach
Credibility 
READ MORE: americans diabetes, diabetes associated, American Diabetes Association, NBC, data presented, scientific sessions, rdna origin, study shows, 69th scientific, phase ii
Related Allvoices Contributions
-
By: safdarjaved
Report: Association of heart disease and diabetes
20 days ago
-
By: agrimonia
Report: Remember all-and a one not healed disease will be less?
about 1 month ago
-
By: MohammadHassan
Report: Ten mantras for a long life
about 1 month ago
-
By: growly20
Report: Alternative Treatments of Diabetes
28 days ago
Related news stories
- Add A News Story |
- Filter By:
- All
- | Local
- News Source: Androscoggin News | 5 months agoNew Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided...
- News Source: Androscoggin News | 5 months agoAmylin Pharmaceuticals, Inc...These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association ( ADA ) in New Orleans . A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S.
- News Source: Androscoggin News | 5 months agoexenatide) injection was not increased compared to patients initiating other antidiabetic therapies...In keeping with the companies' focus on patient safety, Amylin and Lilly continue to pursue a drug safety program that includes thorough...
- News Source: The Courier-Journal | 5 months agoMajor pharmaceutical companies are fighting harder over the millions of patients with diabetes, a lucrative market because the pool of customers is growing with the obesity epidemic -- and they will need daily drugs for life. As the American...
- News Source: The Noblesville Ledger | 5 months agoEli Lilly and Co.'s experimental long-acting version of Byetta lowered blood sugar more than Takeda Pharmaceutical's Actos or Merck's Januvia, and allowed patients to lose more weight, a study showed. Sixty-six percent of diabetics taking Byetta had...
- News Source: Androscoggin News | 5 months agoPatients with type 2 diabetes over the age of 65 years may achieve better hemoglobin A 1c (HbA 1c ) lowering with insulin glargine treatment added to oral hypoglycemic agents than with the combination of NPH insulin and oral agents, according to...
- News Source: Androscoggin News | 5 months agoAn investigational ultra rapid-acting inhalable insulin (Technosphere™ Insulin) at mealtime in combination with basal insulin in patients with type 2 diabetes has glycemic efficacy over 52 weeks that is comparable to twice-daily premixed insulin...
- News Source: Androscoggin News | 5 months agoEli Lilly and Company announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes.
- News Source: Uinta County News | 5 months agoOrexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced positive secondary findings from the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained...
- News Source: Uinta County News | 5 months agoSanofi-aventis U.S. presented results of a new study, "Effects of 1, 2, or 3 Prandial Injections of Insulin Glulisine on Glycemic Control in Type 2 Diabetes Patients on Insulin Glargine and Oral Drugs," evaluating patients adding prandial insulin...
Site Links
Site Topics
Contributions
- Report Your News
- Add your voice and contribute via your cellphone - check out how to Report News via Your Cellphone
- Blog Widget
- Widget for Blog Owner
